All posts by gene3232

GeneCentric Therapeutics Appoints Walter M. Capone as Chief Business Officer and Adds Ellen Lubman to Board of Directors as Company Advances Drug Development Platform

DURHAM, NC, May 30, 2017— GeneCentric Therapeutics, Inc., a precision medicine company dedicated to accelerating drug development by redefining the advanced classification of cancers, today announced the appointments of Walter M. Capone as Chief Business Officer and Ellen Lubman to the company’s Board of Directors.  In his role as CBO, Mr. Capone will lead the expansion in pharmaceutical and biotechnology company drug development collaborations involving GeneCentric’s Cancer Subtyping Platform (CSP™), and will oversee the company’s commercial strategy and growth.  As a Director, Ms. Lubman will augment GeneCentric’s industry and partnership development focus.

VIEW THE ENTIRE PRESS RELEASE

Bristol-Myers Squibb and GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration

GeneCentric secures equity investment from Bristol-Myers Squibb
Bristol-Myers Squibb to explore the use of GeneCentric’s Cancer Subtyping Platform (CSP™)

NEW YORK & DURHAM, N.C.Bristol-Myers Squibb Company (NYSE:BMY) and GeneCentric Diagnostics, Inc. today announced a biomarker research collaboration to explore whether the application of GeneCentric’s Cancer Subtype Platform (CSP™) might be able to identify translational biomarkers for Opdivo (nivolumab), which may help inform future clinical trials. Additionally, GeneCentric announced it has secured equity funding from Bristol-Myers Squibb that will support the clinical development of GeneCentric’s CSP™ and build-out of GeneCentric’s new laboratory in Research Triangle Park.

View the Entire Press Release Here

GeneCentric to Present Data at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

Durham, NC, May 18, 2016 – GeneCentric Diagnostics, Inc., a company devoted to changing the taxonomy of cancer through the analysis of tumor genomics, announced today that it will present new data on its Cancer Subtyping Platform (CSP™) at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting being held June 3-7, 2016 at McCormick Place, Chicago Illinois.

CSP™, GeneCentric’s proprietary core technology, identifies biologic subtypes of cancer through an integrated analysis of tumor genomics.  Cancer subtypes support rational clinical trial design as biomarkers identifying patient cohorts optimally suited for various therapeutic approaches.

Details of the presentation are as follows:

Title: “Immune cell activation among lung adenocarcinoma and squamous cell carcinoma intrinsic subtypes and CD274 (PD-L1) expression.”
Poster Number: 399
Date: Sunday, June 5
Time: 8:00 AM – 11:30 AM CT
Location: McCormick Place, Hall A
Presenter: Hawazin Faruki, DrPH, Chief Scientific Officer, GeneCentric

“We are excited to present our latest immunotherapy related findings on CSP™,” said Dr. Faruki. “We are committed to developing precision medicine tools for enhanced trial design and patient stratification.”

To read the abstract, please visit: http://abstracts.asco.org

About GeneCentric
GeneCentric Diagnostics, Inc. is a company devoted to changing the taxonomy of cancer through an integrated analysis of tumor pathology and genomics. GeneCentric is redefining the advanced classification of cancers through the development and commercialization of its proprietary Cancer Subtype Platform (CSP™). By capturing a comprehensive picture of DNA, RNA and copy number biomarkers, CSP™ can better enable drug developers and oncologists to make more individualized treatment decisions and meet the growing demand for precision medicines. GeneCentric’s first application of CSP™ was launched with partner LabCorp® and is available as HistoPlusSM: Lung Cancer.

For more information, please visit www.genecentric.com.

###
Contact Information:
Dr. Myla Lai-Goldman, CEO
GeneCentric Diagnostics, Inc.
+1-919-973-6544
myla@genecentric.com

 

GeneCentric to Present at the Personalized Medicine World Conference

On January 26, 2016 at 2:00 pm, GeneCentric’s Hawazin Faruki will speak at the Personalized Medicine World Conference (PMWC) 2016 Silicon Valley on “Genomic Tumor Profiling – Advancing Beyond Gene Mutations.”

PMWC 2016 SV, co-hosted with Stanford Health Care and UCSF on January 24-27, will gather 1200 multidisciplinary attendees and key stakeholders from the business, government, healthcare delivery, research and technology arenas to examine the advances and challenges of personalized medicine through a practical lens. See Program, chaired by Atul Butte, here: http://2016sv.pmwcintl.com/all/

GeneCentric to Present Data at the Association for Molecular Pathology 2015 Annual Meeting

Durham, NC, October 30, 2015 – GeneCentric Diagnostics, Inc., a company devoted to changing the taxonomy of cancer through the analysis of tumor genomics, today announced that it will present new data on its lung cancer subtyping product, LSP™ 120, at the Association for Molecular Pathology (AMP) 2015 Annual Meeting being held November 5-7, 2015 at the Austin Convention Center in Austin, Texas. LSP™ 120 was developed using GeneCentric’s Cancer Subtyping Platform (CSP™), which provides precision medicine solutions for patient diagnosis and treatment, as well as advanced patient stratification in drug development and clinical trials.

Details of the presentation are as follows:

Title: “Lung Subtyping Signature for Predicting Survival in Lung Adenocarcinoma and Relationship to Other Gene Expression Prognostic Panels”
Poster Number: ST49
Date: Saturday, November 7
Time: 9:45 a.m. to 10:45 a.m. CT
Location: Austin Convention Center Exhibit Hall
Presenter: Hawazin Faruki, DrPH, Vice President for Clinical Development, GeneCentric

“The performance of LSP™ 120 compares favorably with other prognostic signatures in patients with lung adenocarcinoma, ,” said Dr. Faruki. “We are continuing to develop LSP™ 120 as a tool for the stratification of patients in clinical trials and improved therapeutic management in clinical settings.”

For more information on the AMP 2015 Annual Meeting – Realizing the Dream of Precision Medicine, visit: http://www.amp.org/meetings/2015/.

About GeneCentric

GeneCentric Diagnostics, Inc. is a company devoted to changing the taxonomy of cancer through an integrated analysis of tumor pathology and genomics. GeneCentric is redefining the advanced classification of cancers through the development and commercialization of its proprietary Cancer Subtype Platform (CSP™). By capturing a comprehensive picture of DNA, RNA and copy number biomarkers, CSP™ can better enable drug developers and oncologists to make more individualized treatment decisions and meet the growing demand for precision medicines. GeneCentric’s first application of CSP™ was launched with partner LabCorp® and is available as HistoPlusSM: Lung Cancer.

For more information, please visit www.genecentric.com.

###

Contact Information:
Dr. Myla Lai-Goldman, CEO
GeneCentric Diagnostics, Inc.
+1-919-973-6544
myla@genecentric.com

GeneCentric to Present Data at the 16th World Conference on Lung Cancer

Durham, NC, September 4, 2015 – GeneCentric Diagnostics, Inc., a company devoted to changing the taxonomy of cancer through an integrated analysis of tumor pathology and genomics, today announced that it will present new data on its lung cancer subtyping product, LSP™ 120, at the 16th World Conference on Lung Cancer being held September 6-9, 2015 at the Colorado Convention Center in Denver, CO. LSP™ 120 was developed using GeneCentric’s Cancer Subtyping Platform (CSP™), which provides precision medicine solutions for patient diagnosis and treatment, as well as advanced patient stratification in drug development and clinical trials.

Details of the presentation are as follows:

Title: “Survival Differences of Adenocarcinoma Lung Tumors with Squamous Cell Carcinoma or Neuroendocrine Profiles by Gene Expression Subtyping”
Session: Mini Oral 01 – Pathology
Date: Monday, September 7
Time: 10:45 a.m. to 12:15 p.m. MT
Location: Mile High Ballroom, 2c-3c, Colorado Convention Center
Presenter: Hawazin Faruki, DrPH, Vice President for Clinical Development, GeneCentric

Continue reading GeneCentric to Present Data at the 16th World Conference on Lung Cancer